TYLER PATTON: Open Payments
NPI 1750910816 · MADISON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$667 in 39 payments from 9 companies in 2025. Trend: 2023 $220 · 2024 $634 · 2025 $667
Food & beverage: $667
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $240 |
| ABBVIE INC. | 16 | $239 |
| Novo Nordisk Inc | 3 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Exact Sciences Corporation | 1 | $14 |
Products named: VRAYLAR, BREZTRI, FARXIGA, AIRSUPRA, Wegovy, CAPLYTA, REXULTI, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
